Andrea Botticelli

Pubblicazioni

Titolo Pubblicato in Anno
Circulating CD137+ T cell levels are correlated with response to pembrolizumab treatment in advanced head and neck cancer patients INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 2023
86P {KRAS} G12C mutation and risk of disease recurrence in stage I surgically resected lung adenocarcinoma JOURNAL OF THORACIC ONCOLOGY 2023
Risk of Oral Squamous Cell Carcinoma in One Hundred Patients with Oral Lichen Planus: A Follow-Up Study of Umberto I University Hospital of Rome CANCERS 2023
KRAS G12C mutation and risk of disease recurrence in stage I surgically resected lung adenocarcinoma LUNG CANCER 2023
Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer CLINICAL CANCER RESEARCH 2023
A network approach to define the predictive role of immune profile on tumor response and toxicity of anti PD-1 single agent immunotherapy in patients with solid tumors FRONTIERS IN IMMUNOLOGY 2023
Network approach in liquidomics landscape JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH 2023
The impact of drug–drug Interactions on the toxicity profile of combined treatment with BRAF and MEK Inhibitors in patients with BRAF-mutated metastatic melanoma CANCERS 2023
Systemic therapy de-escalation in advanced ovarian cancer: a new era on the horizon? INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 2023
Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY 2023
PD-L1 testing in metastatic triple negative breast cancer: Results of an Italian survey TUMORI 2023
Rheumatic Diseases Development in Patients Treated by Anti-PD1 Immune Checkpoint Inhibitors: A Single-Centre Descriptive Study LIFE 2023
DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study NEOPLASIA 2023
Do more targets allow more cancer treatments, or not? EUROPEAN JOURNAL OF CANCER 2023
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study FRONTIERS IN ONCOLOGY 2023
Safety of extended interval dosing immune checkpoint inhibitors. A multicenter cohort study JOURNAL OF THE NATIONAL CANCER INSTITUTE 2023
Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 2023
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer NPJ BREAST CANCER 2023
Immune responses and clinical outcomes following the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in advanced breast cancer patients receiving targeted therapies: a prospective study FRONTIERS IN ONCOLOGY 2023
Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study FRONTIERS IN ONCOLOGY 2023

Progetti di Ricerca

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma